Oppenheimer analyst Michael Wiederhorn maintained a Buy rating on Pennant Group (PNTG – Research Report) today and set a price target of $18.00. The company’s shares closed yesterday at $16.88.
According to TipRanks, Wiederhorn is a top 100 analyst with an average return of 15.6% and a 68.05% success rate. Wiederhorn covers the Healthcare sector, focusing on stocks such as Centene, Community Health, and CVS Health.
Currently, the analyst consensus on Pennant Group is a Moderate Buy with an average price target of $17.63.
See today’s best-performing stocks on TipRanks >>
The company has a one-year high of $17.24 and a one-year low of $10.31. Currently, Pennant Group has an average volume of 134.7K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Pennant Group (PNTG) Company Description:
The Pennant Group, Inc. engages in the provision of healthcare services. It operates through the following segments: Home Health and Hospice Services, Senior Living Services, and All Other. The Home Health and Hospice Services segment provides combination of clinical care services such as nursing, speech, occupational and physical therapy, medical social work, and home health aide services. The Senior Living Services segment deals with assisted and independent living and memory care businesses. The All Other segment includes mobile diagnostic and laboratory services. The company was founded on January 24, 2019 and is headquartered in Eagle, ID.
Read More on PNTG:
- Pennant Group Inc Unveils New Investor Presentation Online
- Pennant Reports Fourth Quarter and Fiscal Year 2023 Results
- Pennant Announces Fourth Quarter and Year-End 2023 Earnings Release and Call
- Stephens upgrades Pennant Group on potential to beat 2024 estimates
- Pennant Group upgraded to Overweight from Equal Weight at Stephens
